|
|||||
|
|
Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC |
|
| Authors: | Shuai Li Fangyu Zhou Shengxiang Ren Caicun Zhou |
| Institution: | 1. Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, No. 507 Zhengmin Road, Shanghai 200433, People''s Republic of China;2. Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, No. 507 Zhengmin Road, Shanghai 200433, People''s Republic of China |
| Abstract: | Acquired resistance of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) has been developed as an important clinical problem though EGFR-TKI such as gefitinib, erlotinib and afatinib 0005 and 0010 has achieved 8–14 months of progression free survival in advanced non-small cell lung cancer (NSCLC) patient with EGFR mutation. We report a case here that an advanced lung adenocarcinoma with L858R mutation responded well to pemetrexed rechallenge after acquired resistance of erlotinib. |
| Keywords: | Pemetrexed Rechallenge EGFR-TKI Acquired resistance Chemotherapy NSCLC |
| 本文献已被 ScienceDirect 等数据库收录！ | |